# An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis

> **NCT00681941** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 49 (actual)

## Conditions studied

- Chronic Kidney Disease
- Hyperphosphatemia

## Interventions

- **DRUG:** Sevelamer carbonate (Renvela®)

## Key facts

- **NCT ID:** NCT00681941
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-01
- **Final completion:** 2007-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2015-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681941, "An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00681941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*